Epicardial and liver fat implications in albuminuria: a retrospective study.
Humans
Retrospective Studies
Male
Female
Pericardium
/ diagnostic imaging
Albuminuria
/ epidemiology
Middle Aged
Risk Factors
Aged
Fatty Liver
/ epidemiology
Longitudinal Studies
Adiposity
Time Factors
Adipose Tissue
/ diagnostic imaging
Risk Assessment
Liver
/ diagnostic imaging
Intra-Abdominal Fat
/ physiopathology
Adult
Albuminuria
Cardiovascular disease
Chronic kidney disease
Epicardial adipose tissue
Steatotic liver disease
Visceral adipose tissue
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
22 Aug 2024
22 Aug 2024
Historique:
received:
05
06
2024
accepted:
07
08
2024
medline:
23
8
2024
pubmed:
23
8
2024
entrez:
22
8
2024
Statut:
epublish
Résumé
Albuminuria is considered an early and sensitive marker of kidney dysfunction, but also an independent cardiovascular risk factor. Considering the possible relationship among metabolic liver disease, cardiovascular disease and chronic kidney disease, we aimed to evaluate the risk of developing albuminuria regarding the presence of epicardial adipose tissue and the steatotic liver disease status. A retrospective long-term longitudinal study including 181 patients was carried out. Epicardial adipose tissue and steatotic liver disease were assessed by computed tomography. The presence of albuminuria at follow-up was defined as the outcome. After a median follow up of 11.2 years, steatotic liver disease (HR 3.15; 95% CI, 1.20-8.26; p = 0.02) and excess amount of epicardial adipose tissue (HR 6.12; 95% CI, 1.69-22.19; p = 0.006) were associated with an increased risk of albuminuria after adjustment for visceral adipose tissue, sex, age, weight status, type 2 diabetes, prediabetes, hypertriglyceridemia, hypercholesterolemia, arterial hypertension, and cardiovascular prevention treatment at baseline. The presence of both conditions was associated with a higher risk of developing albuminuria compared to having steatotic liver disease alone (HR 5.91; 95% CI 1.15-30.41, p = 0.033). Compared with the first tertile of visceral adipose tissue, the proportion of subjects with liver steatosis and abnormal epicardial adipose tissue was significantly higher in the second and third tertile. We found a significant correlation between epicardial fat and steatotic liver disease (rho = 0.43 [p < 0.001]). Identification and management/decrease of excess adiposity must be a target in the primary and secondary prevention of chronic kidney disease development and progression. Visceral adiposity assessment may be an adequate target in the daily clinical setting. Moreover, epicardial adipose tissue and steatotic liver disease assessment may aid in the primary prevention of renal dysfunction.
Sections du résumé
BACKGROUND
BACKGROUND
Albuminuria is considered an early and sensitive marker of kidney dysfunction, but also an independent cardiovascular risk factor. Considering the possible relationship among metabolic liver disease, cardiovascular disease and chronic kidney disease, we aimed to evaluate the risk of developing albuminuria regarding the presence of epicardial adipose tissue and the steatotic liver disease status.
METHODS
METHODS
A retrospective long-term longitudinal study including 181 patients was carried out. Epicardial adipose tissue and steatotic liver disease were assessed by computed tomography. The presence of albuminuria at follow-up was defined as the outcome.
RESULTS
RESULTS
After a median follow up of 11.2 years, steatotic liver disease (HR 3.15; 95% CI, 1.20-8.26; p = 0.02) and excess amount of epicardial adipose tissue (HR 6.12; 95% CI, 1.69-22.19; p = 0.006) were associated with an increased risk of albuminuria after adjustment for visceral adipose tissue, sex, age, weight status, type 2 diabetes, prediabetes, hypertriglyceridemia, hypercholesterolemia, arterial hypertension, and cardiovascular prevention treatment at baseline. The presence of both conditions was associated with a higher risk of developing albuminuria compared to having steatotic liver disease alone (HR 5.91; 95% CI 1.15-30.41, p = 0.033). Compared with the first tertile of visceral adipose tissue, the proportion of subjects with liver steatosis and abnormal epicardial adipose tissue was significantly higher in the second and third tertile. We found a significant correlation between epicardial fat and steatotic liver disease (rho = 0.43 [p < 0.001]).
CONCLUSIONS
CONCLUSIONS
Identification and management/decrease of excess adiposity must be a target in the primary and secondary prevention of chronic kidney disease development and progression. Visceral adiposity assessment may be an adequate target in the daily clinical setting. Moreover, epicardial adipose tissue and steatotic liver disease assessment may aid in the primary prevention of renal dysfunction.
Identifiants
pubmed: 39175063
doi: 10.1186/s12933-024-02399-5
pii: 10.1186/s12933-024-02399-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
308Subventions
Organisme : Spanish Institute of Health ISCIII
ID : PI22/00745
Organisme : Spanish Institute of Health ISCIII
ID : PI22/00745
Organisme : Spanish Institute of Health ISCIII
ID : PI22/00745
Organisme : Spanish Institute of Health ISCIII
ID : PI22/00745
Organisme : Spanish Institute of Health ISCIII
ID : PI22/00745
Organisme : Spanish Institute of Health ISCIII
ID : PI22/00745
Organisme : Spanish Institute of Health ISCIII
ID : PI22/00745
Organisme : Spanish Institute of Health ISCIII
ID : PI22/00745
Organisme : Spanish Institute of Health ISCIII
ID : PI22/00745
Organisme : Spanish Institute of Health ISCIII
ID : PI22/00745
Informations de copyright
© 2024. The Author(s).
Références
Mantovani A, Lombardi R, Cattazzo F, Zusi C, Cappelli D, Dalbeni A. MAFLD and CKD: an updated narrative review. Int J Mol Sci. 2022;23:1–11.
doi: 10.3390/ijms23137007
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022;102(5S):S1–127.
Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Chronic kidney disease. Lancet. 2021;398(10302):786–802.
pubmed: 34175022
doi: 10.1016/S0140-6736(21)00519-5
Lezaic V. Albuminuria as a biomarker of the renal disease. Biomarkers Kidney Dis. 2015;81:1–18.
Matsushita K, Coresh J, Sang Y, Chalmers J, Fox C, Guallar E, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol. 2015;3:514–25.
pubmed: 26028594
pmcid: 4594193
doi: 10.1016/S2213-8587(15)00040-6
Mok Y, Ballew SH, Sang Y, Grams ME, Coresh J, Evans M, et al. Albuminuria as a predictor of cardiovascular outcomes in patients with acute myocardial infarction. J Am Heart Assoc. 2019;8(8): e010546.
pubmed: 30947615
pmcid: 6507197
doi: 10.1161/JAHA.118.010546
Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966–86.
pubmed: 37363821
doi: 10.1097/HEP.0000000000000520
Younossi ZM. Non-alcoholic fatty liver disease—a global public health perspective. J Hepatol. 2019;70:531–44.
pubmed: 30414863
doi: 10.1016/j.jhep.2018.10.033
European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO); European Association for the Study of the Liver (EASL). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024. https://doi.org/10.1016/j.jhep.2024.04.031 . (Epub ahead of print)
doi: 10.1016/j.jhep.2024.04.031
Perdomo CM, Avilés-Olmos I, Dicker D, Frühbeck G. Towards an adiposity-related disease framework for the diagnosis and management of obesities. Rev Endocr Metab Disord. 2023;24(5):795–807.
pubmed: 37162651
pmcid: 10492748
doi: 10.1007/s11154-023-09797-2
Ciardullo S, Ballabeni C, Trevisan R, Perseghin G. Liver stiffness, albuminuria and chronic kidney disease in patients with NAFLD: a systematic review and meta-analysis. Biomolecules. 2022;12:1–10.
doi: 10.3390/biom12010105
Muzurović E, Peng CC, Belanger MJ, Sanoudou D, Mikhailidis DP, Mantzoros CS. Nonalcoholic fatty liver disease and cardiovascular disease: a review of shared cardiometabolic risk factors. Hypertension. 2022;79(7):1319–26.
pubmed: 35465684
doi: 10.1161/HYPERTENSIONAHA.122.17982
Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C, Targher G, et al. Nonalcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis of observational studies. J Hepatol. 2016;65(3):589–600.
pubmed: 27212244
doi: 10.1016/j.jhep.2016.05.013
Schonmann Y, Yeshua H, Bentov I, Zelber-Sagi S. Liver fibrosis marker is an independent predictor of cardiovascular morbidity and mortality in the general population. Dig Liver Dis. 2021;53:79–85.
pubmed: 33144054
doi: 10.1016/j.dld.2020.10.014
Wijarnpreecha K, Thongprayoon C, Boonpheng B, Panjawatanan P, Sharma K, Ungprasert P, Pungpapong S, Cheungpasitporn W. Nonalcoholic fatty liver disease and albuminuria: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2018;30(9):986–94.
pubmed: 29787418
doi: 10.1097/MEG.0000000000001169
Mantovani A, Zaza G, Byrne CD, Lonardo A, Zoppini G, Bonora E, et al. Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: a systematic review and meta-analysis. Metabolism. 2017;79:64–76.
pubmed: 29137912
doi: 10.1016/j.metabol.2017.11.003
Bilson J, Mantovani A, Byrne CD, Targher G. Steatotic liver disease, MASLD and risk of chronic kidney disease. Diabetes Metab. 2024;50(1): 101506.
pubmed: 38141808
doi: 10.1016/j.diabet.2023.101506
Perdomo CM, Garcia-Fernandez N, Escalada J. Diabetic kidney disease, cardiovascular disease and non-alcoholic fatty liver disease: a new triumvirate? J Clin Med. 2021;10(9):2040.
pubmed: 34068699
pmcid: 8126096
doi: 10.3390/jcm10092040
Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol. 2022;19:593–606.
pubmed: 35296869
pmcid: 8926097
doi: 10.1038/s41569-022-00679-9
Psychari SN, Rekleiti N, Papaioannou N, Varhalama E, Drakoulis C, Apostolou TS, Iliodromitis EK. Epicardial fat in nonalcoholic fatty liver disease: properties and relationships with metabolic factors, cardiac structure, and cardiac function. Angiology. 2016;67(1):41–8.
pubmed: 25818101
doi: 10.1177/0003319715576672
Petta S, Craxì A. Epicardial fat in patients with non-alcoholic fatty liver disease. J Hepatol. 2015;62:1215.
pubmed: 25617496
doi: 10.1016/j.jhep.2015.01.012
Kim BJ, Cheong ES, Kang JG, Kim BS, Kang JH. Relationship of epicardial fat thickness and nonalcoholic fatty liver disease to coronary artery calcification: from the CAESAR study. J Clin Lipidol. 2016;10(3):619–26.
pubmed: 27206950
doi: 10.1016/j.jacl.2016.01.008
Saritas T, Reinartz SD, Nadal J, Schmoee J, Schmid M, Marwan M, et al. Epicardial fat, cardiovascular risk factors and calcifications in patients with chronic kidney disease. Clin Kidney J. 2020;13:571–9.
pubmed: 32905245
doi: 10.1093/ckj/sfz030
Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, et al. Liver fibrosis in overweight patients. Gastroenterology. 2000;118:1117–23.
pubmed: 10833486
doi: 10.1016/S0016-5085(00)70364-7
Shmilovich H, Dey D, Cheng VY, Rajani R, Nakazato R, Otaki Y, Nakanishi R, Slomka PJ, Thomson LE, Hayes SW, Friedman JD, Gransar H, Wong ND, Shaw LJ, Budoff M, Rozanski A, Berman DS. Threshold for the upper normal limit of indexed epicardial fat volume: derivation in a healthy population and validation in an outcome-based study. Am J Cardiol. 2011;108(11):1680–5.
pubmed: 21880291
pmcid: 3215795
doi: 10.1016/j.amjcard.2011.07.031
Mitchell D, Strydom NB, van Graan CH, Van Der Walt WH. Human surface area: comparison of the du bois formula with direct photometric measurement. Pflügers Arch Eur J Physiol. 1971;325:188–90.
doi: 10.1007/BF00587008
Kaess BM, Pedley A, Massaro JM, Murabito J, Hoffmann U, Fox CS. The ratio of visceral to subcutaneous fat, a metric of body fat distribution, is a unique correlate of cardiometabolic risk. Diabetologia. 2012;55:2622–30.
pubmed: 22898763
pmcid: 3636065
doi: 10.1007/s00125-012-2639-5
Gorostidi M, Sánchez-Martínez M, Ruilope LM, Graciani A, de la Cruz JJ, Santamaría R, et al. Prevalencia de enfermedad renal crónica en España: impacto de la acumulación de factores de riesgo cardiovascular. Nefrologia. 2018;38(6):606–15.
pubmed: 29914761
doi: 10.1016/j.nefro.2018.04.004
Busetto L, Dicker D, Frühbeck G, Halford JCG, Sbraccia P, Yumuk V, Goossens GH. A nesw framework for the diagnosis staging and management of obesity in adults. Nat Med. 2024. https://doi.org/10.1038/s41591-024-03095-3 . (Epub ahead of print).
doi: 10.1038/s41591-024-03095-3
pubmed: 38969880
Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Schattenberg JM, et al. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut. 2022;71:156–62.
pubmed: 33303564
doi: 10.1136/gutjnl-2020-323082
Musso G, Gambino R, Tabibian JH, Ekstedt M, Kechagias S, Hamaguchi M, et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med. 2014;11(7): e1001680.
pubmed: 25050550
pmcid: 4106719
doi: 10.1371/journal.pmed.1001680
Byrne CD, Targher G. NAFLD as a driver of chronic kidney disease. J Hepatol. 2020;72:785–801.
pubmed: 32059982
doi: 10.1016/j.jhep.2020.01.013
Agustanti N, Soetedjo NNM, Damara FA, Iryaningrum MR, Permana H, Bestari MB, et al. The association between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: a systematic review and meta-analysis. Diabetes Metab Syndr Clin Res Rev. 2023;17: 102780.
doi: 10.1016/j.dsx.2023.102780
Chen Y, Bai W, Mao D, Long F, Wang N, Wang K, et al. The relationship between non-alcoholic fatty liver disease and incidence of chronic kidney disease for diabetic and non-diabetic subjects: a meta-analysis. Adv Clin Exp Med. 2022;32:407–14.
doi: 10.17219/acem/155017
Ferris M, Hogan SL, Chin H, Shoham DA, Gipson DS, Gibson K, et al. Obesity, albuminuria, and urinalysis findings in US young adults from the Add Health Wave III study. Clin J Am Soc Nephrol. 2007;2:1207–14.
pubmed: 17942783
doi: 10.2215/CJN.00540107
Zhang HJ, Wang YY, Chen C, Lu YL, Wang NJ, Guo LS. Cardiovascular and renal burdens of metabolic associated fatty liver disease from serial US national surveys, 1999–2016. Chin Med J (Engl). 2021;134:1593–601.
pubmed: 34091530
doi: 10.1097/CM9.0000000000001513
Mantovani A, Turino T, Lando MG, Gjini K, Byrne CD, Zusi C, et al. Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes. Diabetes Metab. 2020;46:296–303.
pubmed: 31786361
doi: 10.1016/j.diabet.2019.11.004
Mikolasevic I, Domislovic V, Ruzic A, Hauser G, Rahelic D, Klobucar-Majanovic S, et al. Elastographic parameters of liver steatosis and fibrosis predict independently the risk of incident chronic kidney disease and acute myocardial infarction in patients with type 2 diabetes mellitus. J Diabetes Complications. 2022;36: 108226.
pubmed: 35803839
doi: 10.1016/j.jdiacomp.2022.108226
Chung GE, Han K, Lee KN, Cho EJ, Bae JH, Yang SY, et al. Combined effects of chronic kidney disease and nonalcoholic fatty liver disease on the risk of cardiovascular disease in patients with diabetes. Biomedicines. 2022;10:1245.
pubmed: 35740267
pmcid: 9219946
doi: 10.3390/biomedicines10061245
Reinhardt M, Cushman TR, Thearle MS, Krakoff J. Epicardial adipose tissue is a predictor of decreased kidney function and coronary artery calcification in youth- and early adult onset type 2 diabetes mellitus. J Endocrinol Invest. 2019;42:979–86.
pubmed: 30674009
doi: 10.1007/s40618-019-1011-8
Hydes T, Kennedy O, Buchanan R, Cuthbertson D, Parkes J, Fraser S, et al. The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective study using UK Biobank data. BMC Med. 2023;21:185.
pubmed: 37198624
pmcid: 10193672
doi: 10.1186/s12916-023-02891-x
Cordeiro AC, Amparo FC, Oliveira MAC, Amodeo C, Smanio P, Pinto IMF, et al. Epicardial fat accumulation, cardiometabolic profile and cardiovascular events in patients with stages 3–5 chronic kidney disease. J Intern Med. 2015;278:77–87.
pubmed: 25556720
doi: 10.1111/joim.12344
Turkmen K, Ozer H, Kusztal M. The relationship of epicardial adipose tissue and cardiovascular disease in chronic kidney disease and hemodialysis patients. J Clin Med. 2022;11:1308.
pubmed: 35268399
pmcid: 8911356
doi: 10.3390/jcm11051308
Katsiki N, Mikhailidis DP. Excessive “orthotopic” fat accumulation: links with cardiometabolic diseases and potential drug treatment. J Cell Physiol. 2020;235(9):6321–2.
pubmed: 31975373
doi: 10.1002/jcp.29573
Miyamori D, Tanaka M, Sato T, Endo K, Mori K, Mikami T, et al. Coexistence of metabolic dysfunction-associated fatty liver disease and chronic kidney disease is a more potent risk factor for ischemic heart disease. J Am Heart Assoc. 2023;12(14): e030269.
pubmed: 37421273
pmcid: 10382120
doi: 10.1161/JAHA.123.030269
Theofilis P, Vordoni A, Kalaitzidis RG. Interplay between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: epidemiology, pathophysiologic mechanisms, and treatment considerations. World J Gastroenterol. 2022;28:5691–706.
pubmed: 36338895
pmcid: 9627426
doi: 10.3748/wjg.v28.i39.5691
Bonora E, Targher G. Increased risk of cardiovascular disease and chronic kidney disease in NAFLD. Nat Rev Gastroenterol Hepatol. 2012;9:372–81.
pubmed: 22565095
doi: 10.1038/nrgastro.2012.79
Wang TY, Wang RF, Bu ZY, Targher G, Byrne CD, Sun DQ, et al. Association of metabolic dysfunction-associated fatty liver disease with kidney disease. Nat Rev Nephrol. 2022;18:259–68.
pubmed: 35013596
doi: 10.1038/s41581-021-00519-y
Hamjane N, Benyahya F, Nourouti NG, Mechita MB, Barakat A. Cardiovascular diseases and metabolic abnormalities associated with obesity: What is the role of inflammatory responses? A systematic review. Microvasc Res. 2020;131: 104023.
pubmed: 32485192
doi: 10.1016/j.mvr.2020.104023
Gómez-Ambrosi J, Salvador J, Páramo JA, Orbe J, De Irala J, Diez-Caballero A, et al. Involvement of leptin in the association between percentage of body fat and cardiovascular risk factors. Clin Biochem. 2002;35:315–20.
pubmed: 12135695
doi: 10.1016/S0009-9120(02)00320-X
Frühbeck G, Gómez-Ambrosi J. Control of body weight: a physiologic and transgenic perspective. Diabetologia. 2003;46:143–72.
pubmed: 12627314
doi: 10.1007/s00125-003-1053-4
Katsiki N, Athyros VG, Mikhailidis DP. Abnormal Peri-Organ or Intra-organ Fat (APIFat) deposition: an underestimated predictor of vascular risk? Curr Vasc Pharmacol. 2016;14(5):432–41.
pubmed: 27456108
doi: 10.2174/1570161114666160722112738
Ferreira FG, Reitz LK, Valmorbida A, Papini Gabiatti M, Hansen F, Faria Di Pietro P, et al. Metabolically unhealthy and overweight phenotypes are associated with increased levels of inflammatory cytokines: a population-based study. Nutrition. 2022;96: 111590.
pubmed: 35180622
doi: 10.1016/j.nut.2022.111590
Gómez-Ambrosi J, Salvador J, Rotellar F, Silva C, Catalán V, Rodríguez A, Jesús Gil M, Frühbeck G. Increased serum amyloid A concentrations in morbid obesity decrease after gastric bypass. Obes Surg. 2006;16(3):262–9.
pubmed: 16545156
doi: 10.1381/096089206776116525
Catalán V, Gómez-Ambrosi J, Rodrígue A, Ramírez B, Rotellar F, Valentí V, et al. Increased levels of calprotectin in obesity are related to macrophage content: impact on inflammation and effect of weight loss. Mol Med. 2011;17:1157–67.
pubmed: 21738950
pmcid: 3321803
doi: 10.2119/molmed.2011.00144
Cypess AM. Reassessing human adipose tissue. N Engl J Med. 2022;386:768–79.
pubmed: 35196429
doi: 10.1056/NEJMra2032804
Sakers A, De Siqueira MK, Seale P, Villanueva CJ. Adipose-tissue plasticity in health and disease. Cell. 2022;185:419–46.
pubmed: 35120662
pmcid: 11152570
doi: 10.1016/j.cell.2021.12.016
Stenvinkel P, Chertow GM, Devarajan P, Levin A, Andreoli SP, Bangalore S, et al. Chronic inflammation in chronic kidney disease progression: role of Nrf2. Kidney Int Reports. 2021;6:1775–87.
doi: 10.1016/j.ekir.2021.04.023
De Fano M, Bartolini D, Tortoioli C, Vermigli C, Malara M, Galli F, et al. Adipose tissue plasticity in response to pathophysiological cues: a connecting link between obesity and its associated comorbidities. Int J Mol Sci. 2022;23:5511.
pubmed: 35628322
pmcid: 9141504
doi: 10.3390/ijms23105511
Nguyen Dinh Cat A, Montezano AC, Burger D, Touyz RM. Angiotensin II, NADPH oxidase, and redox signaling in the vasculature. Antioxidants Redox Signal. 2013;19:1110–20.
doi: 10.1089/ars.2012.4641
Perdomo CM, Frühbeck G, Escalada J. Impact of nutritional changes on nonalcoholic fatty liver disease. Nutrients. 2019;11:1–25.
doi: 10.3390/nu11030677
Frühbeck G, Catalán V, Rodríguez A, Ramírez B, Becerril S, Salvador J, et al. Adiponectin-leptin ratio is a functional biomarker of adipose tissue inflammation. Nutrients. 2019;11:1–13.
doi: 10.3390/nu11020454
Park YC, Lee S, Kim YS, Park JM, Han K, Lee H, et al. Serum leptin level and incidence of CKD: a longitudinal study of adult enrolled in the Korean genome and epidemiology study(KoGES). BMC Nephrol. 2022;23:1–9.
doi: 10.1186/s12882-022-02795-7
D’Marco L, Puchades MJ, Panizo N, Romero-Parra M, Gandía L, Giménez-Civera E, et al. Cardiorenal fat: a cardiovascular risk factor with implications in chronic kidney disease. Front Med. 2021;8:1–8.
Pincu Y, Yoel U, Haim Y, Makarenkov N, Maixner N, Shaco-Levy R, et al. Assessing obesity-related adipose tissue disease (OrAD) to improve precision medicine for patients living with obesity. Front Endocrinol (Lausanne). 2022;13:1–17.
doi: 10.3389/fendo.2022.860799
Lonardo A, Mantovani A, Targher G, Baffy G. Nonalcoholic fatty liver disease and chronic kidney disease: epidemiology, pathogenesis, and clinical and research implications. Int J Mol Sci. 2022;23:13320.
pubmed: 36362108
pmcid: 9654863
doi: 10.3390/ijms232113320
García-Carro C, Vergara A, Bermejo S, Azancot MA, Sellarés J, Soler MJ. A nephrologist perspective on obesity: from kidney injury to clinical management. Front Med. 2021;8: 655871.
doi: 10.3389/fmed.2021.655871
Zhang X, Lerman LO. Obesity and renovascular disease. Am J Physiol - Ren Physiol. 2015;309:F273–9.
doi: 10.1152/ajprenal.00547.2014
Roderburg C, Krieg S, Krieg A, Demir M, Luedde T, Kostev K, et al. Non - alcoholic fatty liver disease (NAFLD )is associated with an increased incidence of chronic kidney disease (CKD). Eur J Med Res. 2023. https://doi.org/10.1186/s40001-023-01114-6 .
doi: 10.1186/s40001-023-01114-6
pubmed: 37062837
pmcid: 10108448
Radaelli MG, Martucci F, Perra S, Accornero S, Castoldi G, Lattuada G, Manzoni G, Perseghin G. NAFLD/NASH in patients with type 2 diabetes and related treatment options. J Endocrinol Invest. 2018;41(5):509–21.
pubmed: 29189999
doi: 10.1007/s40618-017-0799-3
Benlloch S, Moncho F, Górriz JL. Targeting metabolic-associated fatty liver disease in diabetic kidney disease: a call to action. Nefrologia (Engl Ed). 2024;44(2):129–38.
pubmed: 38565488
doi: 10.1016/j.nefroe.2024.03.009
Perdomo AC, Ingianna PD, Escalada J, Petta S, Gómez R, Ampuero J. Nonalcoholic fatty liver disease and the risk of metabolic comorbidities: how to manage in clinical practice Pol. Arch Intern Med. 2020;130(11):975–85.
Hu S, Li X, Sun Y, Wu S, Lan Y, Chen S, Wang Y, Liao W, Wang X, Zhang D, Yuan X, Gao J, Wang L. Short-term weight loss decreased the risk of chronic kidney disease in men with incident nonalcoholic fatty liver disease. Obesity (Silver Spring). 2022;30(7):1495–506.
pubmed: 35730626
doi: 10.1002/oby.23459
Perdomo CM, Cohen RV, Sumithran P, Clément K, Frühbeck G. Contemporary medical, device, and surgical therapies for obesity in adults. Lancet. 2023;401(10382):1116–30.
pubmed: 36774932
doi: 10.1016/S0140-6736(22)02403-5
Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, MAESTRO-NASH Investigators. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390(6):497–509.
pubmed: 38324483
doi: 10.1056/NEJMoa2309000
Kokkorakis M, Muzurović E, Volčanšek Š, Chakhtoura M, Hill MA, Mikhailidis DP, Mantzoros CS. Steatotic liver disease: pathophysiology and emerging pharmacotherapies. Pharmacol Rev. 2024;76(3):454–99.
pubmed: 38697855
doi: 10.1124/pharmrev.123.001087
Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, Yoneda M, Behling C, Cummings OW, Tang Y, Brouwers B, Robins DA, Nikooie A, Bunck MC, Haupt A, Sanyal AJ, SYNERGY-NASH Investigators. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024. https://doi.org/10.1056/NEJMoa2401943 . (Epub ahead of print).
doi: 10.1056/NEJMoa2401943
pubmed: 38856224
Gerdes C, Müller N, Wolf G, Busch M. Nephroprotective properties of antidiabetic drugs. J Clin Med. 2023;12:3377.
pubmed: 37240483
pmcid: 10219007
doi: 10.3390/jcm12103377
Muzurović EM, Vujošević S, Mikhailidis DP. Can we decrease epicardial and pericardial fat in patients with diabetes? J Cardiovasc Pharmacol Ther. 2021;26(5):415–36.
pubmed: 33844605
doi: 10.1177/10742484211006997